Compare CLMB & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CLMB | CTMX |
|---|---|---|
| Founded | 1982 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Retail: Computer Software & Peripheral Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 620.7M | 716.9M |
| IPO Year | 1996 | 2015 |
| Metric | CLMB | CTMX |
|---|---|---|
| Price | $32.62 | $2.32 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $32.33 | $12.25 |
| AVG Volume (30 Days) | 127.1K | ★ 3.1M |
| Earning Date | 10-28-2026 | 11-09-2026 |
| Dividend Yield | ★ 0.13% | N/A |
| EPS Growth | ★ 14.29 | N/A |
| EPS | ★ 0.48 | N/A |
| Revenue | ★ $652,517,000.00 | $76,201,000.00 |
| Revenue This Year | $12.32 | N/A |
| Revenue Next Year | $9.32 | $1.24 |
| P/E Ratio | $67.89 | ★ $22.58 |
| Revenue Growth | ★ 40.14 | N/A |
| 52 Week Low | $15.25 | $2.16 |
| 52 Week High | $79.12 | $8.21 |
| Indicator | CLMB | CTMX |
|---|---|---|
| Relative Strength Index (RSI) | 56.76 | 42.70 |
| Support Level | $30.82 | $2.20 |
| Resistance Level | $34.14 | $2.61 |
| Average True Range (ATR) | 1.08 | 0.16 |
| MACD | -0.17 | 0.02 |
| Stochastic Oscillator | 56.71 | 45.56 |
Climb Global Solutions Inc is a cloud-based, value-added IT distribution and solutions company specializing in emerging technologies. It operates across the USA, Canada, United Kingdom, and Europe through multiple business units, including Climb Channel Solutions, Sigma, Grey Matter, Interwork, and TechXtend. The company is organized into two reportable operating segments. The Distribution segment distributes technical software to corporate resellers, value-added resellers (VARs), consultants, and systems integrators under the name Climb Channel Solutions. The Solutions segment is a cloud solutions provider and value-added reseller of software, hardware, and services to customers under the name Grey Matter.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.